The National Institutes of Health (NIH) has awarded a grant to support research into immune mechanisms that could allow for the reversal of fibrosis, or tissue scarring, in idiopathic pulmonary fibrosis (IPF). The $469,034 award went to Narendiran Rajasekaran, PhD, and Archana Varadaraj, PhD, both of whom are assistant…
Scientists have developed a new lab-grown three-dimension (3D) microtissue model that replicates the key features of the idiopathic pulmonary fibrosis (IPF) microenvironment better than other cellular and animal models, and that enables more robust screening of potential therapies. When the model was generated using lung cells collected from IPF…
Reviva Pharmaceuticals is planning to seek the U.S. Food and Drug Administration’s (FDA) permission to begin Phase 2 clinical trials testing its investigational therapy brilaroxazine in people with idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH). “We … expect to begin regulatory submissions to the FDA…
An inhalable therapeutic is being developed using pressure-treated yeast beta-glucan for people with COVID-19 as well as other severe lung diseases, including idiopathic pulmonary fibrosis (IPF). Beta-glucans are fiber compounds that are naturally found in the cell walls of grains, bacteria, and fungi, such as yeast. Ceapro, a biotechnology…
The Microbiome Therapeutics Innovation Group (MTIG), a coalition of companies working to develop U.S. Food and Drug Administration (FDA)-microbiome-based therapies, announced the addition of Alveolus Bio to its group. Alveolus has more than a decade of research into neutrophilic inflammation — an asthmatic inflammation driven by specific white…
Alterations in lactic acid metabolism — part of the process that allows the body to produce energy in the absence of oxygen — were found in lung tissues collected from patients with idiopathic pulmonary fibrosis (IPF), a recent study reported. These findings suggest that lactic acid metabolism may be…
High-flow nasal cannula oxygen therapy (HFNC) increases exercise tolerance — improving endurance times and reducing leg fatigue — in adults with stable idiopathic pulmonary fibrosis (IPF) having exercise-induced low blood oxygen levels, according to a small trial in Japan. Notably, HFNC’s benefits were superior to those of standard oxygen therapy,…
A signaling molecule called interleukin 35 (IL-35) is at unusually high levels in lung tissues from mice and in people with pulmonary fibrosis (PF), and seems to play a role in slowing disease progression, a study found. These findings indicate that IL-35 might be a new therapeutic target for…
People with idiopathic pulmonary fibrosis (IPF) had the same mortality and hospitalization rates, and incurred similar healthcare costs, whether they were treated with Esbriet (pirfenidone) or Ofev (nintedanib), a German insurance claims analysis showed. However, the analysis — conducted over five years and involving more than 1,000 patients…
The biotech startup ResBiotic has created a lung disease-focused pharmaceutical spin-off — Alveolus Bio — and launched its first probiotic-based consumer health product called resB Lung Support. The parent company, based in Birmingham, Alabama, and its subsidiary are using $4.5 million in seed funding “to transform the respiratory care landscape…
Get regular updates to your inbox.
